AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

Pemovska T.; Johnson E.; Kontro M.; Repasky G. A.; Chen J.; Wells P.; Cronin C.; McTigue M.; Kallioniemi O.; Porkka K.; Murray B. W.; Wennerberg K.

首页> 外文期刊>Annals of hematology >AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

【24h】

AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

机译：AXITINIB以截然不同的选择性靶向靶向关守突变BCR-ABL1（T315I）驱动的白血病

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of hematology 》 |2015年第1期| 共2页
作者
Pemovska T.; Johnson E.; Kontro M.; Repasky G. A.; Chen J.; Wells P.; Cronin C.; McTigue M.; Kallioniemi O.; Porkka K.; Murray B. W.; Wennerberg K.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类血液及淋巴系疾病 ;
关键词

相似文献

外文文献
中文文献
专利

1. AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion [J] . Pemovska T., Johnson E., Kontro M., Annals of hematology . 2015 ,第Suppla1期

机译：AXITINIB以截然不同的选择性靶向靶向关守突变BCR-ABL1（T315I）驱动的白血病
2. Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation [J] . Deininger Michael W., Rea Delphine, Lang Fabian, Clinical lymphoma, myeloma & leukemia . 2019 ,第Suppla1期

机译：ASCIMINIB的疗效和安全性是靶向Myristoyl结合位点的特异性变革BCR-ABL1抑制剂，患有T315i突变的慢性骨髓性白血病（CML）患者
3. Validation of a Drosophila model of wild-type and T315I mutated BCR-ABL1 in chronic myeloid leukemia: an effective platform for treatment screening [J] . Amani Al Outa, Dana Abubaker, Ali Bazarbachi, Haematologica . 2020 ,第2期

机译：慢性骨髓白血病野生型和T315I突变BCR-ABL1的<斜视>果蝇模型：治疗筛查有效平台
4. Novel Inhibitors of T315I Mutant BCR-ABL1 Tyrosine Kinase for Chronic Myeloid Leukemia Disease Through Fragment-Based Drug Design [C] . Satya Anindita, Atika Marnolia, Hersal Hermana Putra, International symposium on bioinformatics research and applications . 2018

机译：T315I突变BCR-ABL1酪氨酸激酶的新型抑制剂通过基于片段的药物设计治疗慢性粒细胞白血病
5. New strategies for targeted chronic myeloid leukemia therapy: Disrupting BCR-ABL1 dimerization and secondary leukemia-specific pathways [D] . Woessner, David W. 2013

机译：针对性慢性粒细胞白血病治疗的新策略：破坏BCR-ABL1二聚化和继发性白血病特异性途径
6. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib [O] . Benjamin Hanfstein, Michael Lauseker, Rüdiger Hehlmann, 2014

机译：伊马替尼一线治疗下e13a2与e14a2 BCR-ABL1驱动的慢性粒细胞白血病的不同特征
7. Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib [O] . Hanfstein Benjamin, Lauseker Michael, Hehlmann Rüdiger, 2015

机译：伊马替尼一线治疗下e13a2与e14a2 BCR-ABL1驱动的慢性粒细胞白血病的不同特征

AXITINIB Targets Gatekeeper-Mutant BCR-ABL1(T315I)-Driven Leukemia in a Distinct And Selective Fashion

著录项

相似文献

相关主题

期刊订阅